Calton & Associates, Inc. Allogene Therapeutics, Inc. Transaction History

Calton & Associates, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 07, 2024	BUY	$2.28 - $3.5 $48,016 - $73,710	21,060 New	21,060 $67,000
Q2 2023 Jul 24, 2023	SELL	$4.53 - $6.74 $3,868 - $5,755	-854 Reduced 3.59%	22,907 $113,000
Q1 2023 Apr 19, 2023	BUY	$4.92 - $8.21 $36,639 - $61,139	7,447 Added 45.65%	23,761 $117,000
Q4 2022 Jan 18, 2023	BUY	$5.62 - $11.11 $27,234 - $53,839	4,846 Added 42.26%	16,314 $0
Q3 2022 Oct 31, 2022	SELL	$10.32 - $17.28 $60,722 - $101,675	-5,884 Reduced 33.91%	11,468 $123,000
Q2 2022 Jul 12, 2022	SELL	$6.78 - $12.28 $6,624 - $11,997	-977 Reduced 5.33%	17,352 $197,000
Q1 2022 Apr 12, 2022	BUY	$7.65 - $15.29 $140,216 - $280,250	18,329 New	18,329 $166,000
Q4 2021 Jan 13, 2022	SELL	$13.13 - $24.52 $125,338 - $234,067	-9,546 Closed	0 $0
Q3 2021 Nov 05, 2021	BUY	$21.01 - $27.64 $200,561 - $263,851	9,546 New	9,546 $245,000
Q2 2021 Aug 11, 2021	SELL	$23.49 - $35.8 $142,513 - $217,198	-6,067 Closed	0 $0
Q1 2021 May 03, 2021	BUY	$25.79 - $39.02 $156,467 - $236,734	6,067 New	6,067 $214,000

166

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $217M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Calton & Associates, Inc., based on Form 13F filings with the SEC.

Stay updated on Calton & Associates, Inc. with notifications on news.